13 January 2022 | News
iPSC technology to develop off-the-shelf natural killer (NK) cell therapy
Photo Credit: Freepik
Singapore-based SCG Cell Therapy Pte Ltd (“SCG”), a leading biotechnology company, has acquired the rights to human “induced pluripotent stem cell” (iPSC) technology, from the Agency for Science, Technology and Research (“A*STAR”)’s Accelerate Technologies Pte Ltd (“A*ccelerate”).
The technology enables SCG to expand its cell therapy product portfolio and develop off-the-shelf cell-based cancer immunotherapy. “iPSC is a technology that is derived from skin or blood cells that are reprogrammed back into an embryonic-like pluripotent state that can produce any type of human cell.
This would allow for the production of a steady source of cells for all types of cell therapy,” said Dr. Adrian Teo, Principal Investigator at A*STAR’s Institute of Molecular and Cell Biology (IMCB). SCG will use the iPSC technology to develop off-the-shelf natural killer (NK) cell therapy.
“The advanced iPSC technology developed by A*STAR provides a promising future in mass NK cell production, offering standardized, off-the-shelf cell therapy products at a more affordable cost and more readily available to patients”, said Frank Wang Shuli, Chief Executive Officer of SCG Cell Therapy.
Australia conducts new rese…
Is Singapore ready to becom…
Laboratories in times of so…
Waters launches ACQUITY PRE…
The lasting benefits of decentraliz
For the automation portfolio, we se
Is Singapore ready to become a glob
India develops AI tool to detect CO
China focuses on next-generation in
BioNTech to establish first South E
WHO lists China's Sinopharm COVID-1
Taiwan shares 150 oxygen concentrat
Is 'Digital Reset' the way forward for Life Sciences sector in 2022?
1 North Bridge Road,
#08-08 High Street Centre,
Email : email@example.com
Visit Our Digital Magazine :
© 2022 MM Activ Sci-Tech Communications. All rights reserved | Disclaimer
Web Interface Conceived and Powered By : SCI Knowledge Interlinks